Cizzle Biotechnology Holdings PLC (CIZ) AI Stock Analysis

• Market Cap: £6.14M
• Dividend Yield: N/A
• Average Volume (3M): 1.23M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 396,391,780
• 10 Day Avg. Volume: 655,017
• 30 Day Avg. Volume: 1,232,506
• PEG Ratio: 0.00
• Price to Book (P/B): 0.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: 1.50p ▼(-3.23% Downside)

The score is held down primarily by weak financial performance (pre-revenue, ongoing losses, cash burn, and a sharply reduced equity cushion), with technical indicators also pointing to subdued momentum. Valuation metrics provide limited support due to negative earnings and no dividend.

Cizzle Biotechnology Holdings PLC Business Overview & Revenue Model

Company Description

Cizzle Biotechnology Holdings Plc engages in development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.

How the Company Makes Money

Cizzle Biotechnology Holdings PLC Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	0.00	0.00	-963.00K	-3.96M	-306.00K
Net Income	-2.17K	-1.72K	-910.00K	-3.92M	-306.00K
Balance Sheet
Total Assets	492.00K	1.69M	2.79M	1.16M	90.00K
Cash, Cash Equivalents and Short-Term Investments	387.00K	1.56M	478.00K	875.00K	84.00K
Total Debt	0.00	0.00	0.00	0.00	10.00K
Total Liabilities	410.00K	186.00K	145.00K	218.00K	58.00K
Stockholders Equity	82.00K	1.51M	2.64M	937.00K	32.00K
Cash Flow
Free Cash Flow	-358.00K	-639.00K	-872.00K	-1.21M	-294.00K
Operating Cash Flow	-358.00K	-639.00K	-872.00K	-1.01M	-294.00K
Investing Cash Flow	0.00	0.00	-120.00K	-154.00K	0.00
Financing Cash Flow	579.00K	305.00K	595.00K	2.03M	10.00

Cizzle Biotechnology Holdings PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FUM	52 Neutral	£7.59M	-0.63	-115.97%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TCF	45 Neutral	£4.51M	-1.62	-53.79%	―	―	85.56%
CIZ	43 Neutral	£6.14M	-5.54	-433.59%	―	―	―
OPTI	43 Neutral	£6.09M	-42.14	-2.42%	―	―	―
NFX	42 Neutral	£6.12M	-0.67	-153.80%	―	―	-616.67%
VAL	41 Neutral	£2.90M	-0.27	―	―	418.49%	27.86%

Cizzle Biotechnology Holdings PLC Corporate Events

Cizzle Biotechnology Secures Additional Funding to Expand Lung Cancer Test

Cizzle Biotechnology Holdings PLC has secured an additional £250,000 through convertible loan notes from investor Frazer Lang to support the commercialization of its CIZ1B biomarker test for early lung cancer detection. This funding will aid in expanding the test’s availability in North America, the UK, and Europe, and supports ongoing collaborations with medical partners, including the NHS, to enhance early cancer diagnosis capabilities.

Cizzle Biotechnology Expands UK Presence with New Partnership for Cancer Detection

Cizzle Biotechnology Holdings PLC has signed a Letter of Intent with a leading UK clinical diagnostic group to verify and validate its CIZ1B biomarker test in partnership with the NHS. This agreement could lead to the group becoming the exclusive UK supplier of the test, aligning with Cizzle’s strategy to expand its early lung cancer detection services in the UK and Europe. The company has already secured a licensing agreement in North America and the Caribbean, and aims to support its US partner in obtaining CLIA accreditation. This move is part of Cizzle’s broader strategy to enhance early cancer detection globally, in line with NHS goals to improve cancer survival rates.

Cizzle Biotechnology Expands UK Presence with New NHS Partnership

Cizzle Biotechnology Holdings PLC has signed a Letter of Intent with a leading UK clinical diagnostic group to verify and validate its CIZ1B biomarker test in partnership with the NHS. This move is part of Cizzle’s strategy to expand its early lung cancer detection test across the UK and Europe, aligning with the NHS’s goals to improve early cancer diagnosis. The company has already secured a licensing agreement in North America and the Caribbean and is working on further partnerships to enhance its global market presence.

Cizzle Biotechnology Relocates Headquarters to The Shard

Cizzle Biotechnology Holdings PLC has announced a change in its registered office and UK head office to Level 19, The Shard, London, effective immediately. This strategic move could potentially enhance the company’s operational efficiency and visibility within the industry, benefiting stakeholders and reinforcing its market presence in early cancer diagnostics.